Sandoz receives positive CHMP opinion for proposed biosimilar infliximab

Sandoz receives positive CHMP opinion for proposed biosimilar infliximab Rheumatology 2018;57:e52 doi:10.1093/rheumatology/key115 RHEUMATOLOGY Advance Access publication 5 April 2018 Global News Item Sandoz receives positive CHMP opinion for proposed biosimilar infliximab Posted on 23 March 2018 . This recommendation marks the third CHMP positive opinion granted for a Sandoz biosimilar in 12 months, . Sandoz is seeking approval of biosimilar infliximab for R R V V following Erelzi and Rixathon ; Sandoz is on track to use in all indications of its reference medicine across launch several biosimilars of major oncology and im- gastroenterology, rheumatology and dermatology munology biologics by 2020 . Positive opinion is based on a comprehensive clinical and non-clinical data package that is expected to con- Please read the full press release here: https://www.pharmi firm that Sandoz biosimilar infliximab matches the ref- web.com/pressreleases/pressrel.asp?ROW_ID=271654 erence medicine The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com Downloaded from https://academic.oup.com/rheumatology/article-abstract/57/6/e52/4961500 by Ed 'DeepDyve' Gillespie user on 17 June 2018 NEWS ITEM http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Rheumatology Oxford University Press

Sandoz receives positive CHMP opinion for proposed biosimilar infliximab

Rheumatology , Volume Advance Article (6) – Apr 5, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/ou_press/sandoz-receives-positive-chmp-opinion-for-proposed-biosimilar-1jTbW1hjGO
Publisher
Oxford University Press
Copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
ISSN
1462-0324
eISSN
1462-0332
D.O.I.
10.1093/rheumatology/key115
Publisher site
See Article on Publisher Site

Abstract

Rheumatology 2018;57:e52 doi:10.1093/rheumatology/key115 RHEUMATOLOGY Advance Access publication 5 April 2018 Global News Item Sandoz receives positive CHMP opinion for proposed biosimilar infliximab Posted on 23 March 2018 . This recommendation marks the third CHMP positive opinion granted for a Sandoz biosimilar in 12 months, . Sandoz is seeking approval of biosimilar infliximab for R R V V following Erelzi and Rixathon ; Sandoz is on track to use in all indications of its reference medicine across launch several biosimilars of major oncology and im- gastroenterology, rheumatology and dermatology munology biologics by 2020 . Positive opinion is based on a comprehensive clinical and non-clinical data package that is expected to con- Please read the full press release here: https://www.pharmi firm that Sandoz biosimilar infliximab matches the ref- web.com/pressreleases/pressrel.asp?ROW_ID=271654 erence medicine The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com Downloaded from https://academic.oup.com/rheumatology/article-abstract/57/6/e52/4961500 by Ed 'DeepDyve' Gillespie user on 17 June 2018 NEWS ITEM

Journal

RheumatologyOxford University Press

Published: Apr 5, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off